Founded in 2019, Bengaluru-based healthtech startup Vieroots, had got Suniel Shetty as an early stage investor in 2020.
The company uses an advanced technology called EPLIMO and is into personal consumer genomics and epigenetic management.
“Vieroots is perhaps the first personalised epigenetic lifestyle modification company, probably in the world. What we are doing is converging the genomic data and metabolic data to develop the Epigenetic Lifestyle Modifications recommendations best suited to people. This is done with the help of high end Artificial Intelligence, and this is the highest level of personalized health available right now,” the company chairman Sajeev Nair said.
“The fund will be used to expand the user base as well as launching experience centers in the metro cities. We also plan global expansion in the meanwhile,” he said.
In the second year of operations itself the company has broken even with a revenue of about Rs.15 crore “We aim to at least double if not triple this in the next 18-24 months,” Nair said.
Discover the stories of your interest
Vieroots has introduced next-generation wellness with EPLIMO, a pioneering new-age healthcare solution based on geno-metabolic assessment.
EPLIMO assesses the risk of developing lifestyle diseases such as diabetes, obesity, high BP, cardiovascular diseases, cancer etc. and design lifestyle modifications spanning diet, supplements and exercises to keep health at its optimum level. In addition to the proprietory program EPLIMO, Vieroots also has launched 19 nutritional supplements in Indian market.
Products include dietary supplements like Magnesium, Zinc and also few unique ayurvedic formulations.
“I am an ardent believer of preventive wellness, as wellness is far cheaper than illness. I found the concept of bio-hacking and anti-aging introduced by Vieroots quite exciting. Through a personalized lifestyle modification programme, Vieroots offers holistic wellness involving purification of the body and restoration of nutrients,” said Suniel Shetty.
Vieroots is backed by a knowledge-driven and tech-led wellness model. Thanks to the growing awareness on wellness, we are looking at immense growth for Vieroots, going forward,” he added.
The global market for genomics is estimated to be worth about $17 billion, Deloitte said in a recent note.
“Based on our analysis of market data, we expect to see 14 percent annual growth over the next several years. The field of genomics is a significant disruptive force that could redefine health care, and we are only beginning to tap its potential. Clinicians are empowered by new diagnostic and treatment paradigms. Genomics and AI are driving more predictive, preventive, personalised and participatory medicine,” Deloitte said.
“This shift has been driven by technological and scientific advancements including digital therapeutics, epigenetics and AI,” it added.
